M&A Toolkit
Chinese M&A in Poland could see push once the dust settles
- Silk Road geopolitics could play role in M&A pickup
- Infrastructure & energy, construction, pharma & cosmetics among potential target sectors
- Deal execution, government regulations hamper dealmaking
Presentations and interviews from the 2019 Italian M&A and Private Equity Forum
Cyber security in M&A deals and value creation strategies were just some of the topics discussed at the Italian M&A and Private Equity Forum.
Matthew Robinson
Event Director, Acuris
All the insights from the Swiss M&A and Private Equity Forum 2019
We've put together all the insights from the 2019 Swiss M&A and Private Equity Forum in case you missed the event. Presentations include the macro-outlook for corporates and lessons learnt in M&A.
CEE M&A remained stable in 2019, dipping 15.9% by value versus 25% across Europe
Mergermarket, the leading provider of M&A data and intelligence, has released new data finding that the Central and Eastern Europe (CEE) region has remained resolute in 2019, dipping by 15.9% by value versus around 25% across Europe.
Irish private equity buyouts soar in 2019 as tech dominates M&A
Mergermarket, the leading provider of M&A data and intelligence, has released new data finding that Irish private equity buyouts stand at their second highest YTD volume on Mergermarket record, with 21 deals worth EUR 1.9bn. Irish private equity buyouts have also accounted for 19.8% of M&A deals so far this year, the highest percentage since the financial crisis.
Saudi Arabia sees highest deal value on record at USD 72.5 billion
Mergermarket, the leading provider of M&A data and intelligence, has today released research showing that Saudi Arabia saw a jump in M&A volume and value (14 deals worth USD 72.6bn) during the first half of 2019, due to the blockbuster USD 70bn SABIC deal announced in 1Q19, the region’s highest value deal on record and the second largest industrials and chemicals deal globally.
Dealcast: Allergan reaction
The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.
Dealcast: KKR’s play for Axel Springer
German media conglomerate Axel Springer [ETR:SPR] has caught the eye of KKR [NYSE:KKR]. With Axel Springer’s founding family supporting its bid, KKR has an easier route towards taking the target off the market. Activistmonitor editor William Mace and Mergermarket’s resident DACH expert Emma-Victoria Farr joined us to discuss what the deal could mean for Axel Springer’s future.
Spanish private equity continues to drive activity reaching EUR 3bn in 1Q19
Mergermarket, the leading provider of M&A data and intelligence, has released research showing that in 1Q19, Spanish private equity continued to be active, with buyouts in the region reaching EUR3bn (18 deals), while exits reached EUR 2bn (7 deals), up from EUR 1.3bn and EUR 1.5bn for buyouts and exits, respectively in 4Q18.
Confirm cancellation
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.
Close